Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy

Biomater Sci. 2020 Feb 21;8(4):1101-1105. doi: 10.1039/c9bm01564g. Epub 2019 Dec 3.

Abstract

For mRNA mediated cancer immunotherapy, Pam3 was incorporated as an adjuvant within lipid nanoparticles (LNPs) with OVA mRNA. The developed Pam3 incorporated LNPs showed successful expression of tumor antigens with enhanced immune stimulation. We demonstrated that the synergies of Pam3 LNPs could greatly improve the efficacy of tumor prevention by mRNA vaccines.

MeSH terms

  • Adjuvants, Immunologic / administration & dosage*
  • Adjuvants, Immunologic / chemistry
  • Animals
  • Cancer Vaccines / administration & dosage
  • Cancer Vaccines / therapeutic use
  • Cell Line
  • Humans
  • Immunotherapy
  • Injections, Intramuscular
  • Lipids / chemistry
  • Lipopeptides / administration & dosage*
  • Lipopeptides / chemistry
  • Lipopeptides / therapeutic use
  • Mice
  • Nanoparticles
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Ovalbumin / genetics*
  • Particle Size
  • RNA, Messenger / administration & dosage*
  • RNA, Messenger / chemistry
  • Xenograft Model Antitumor Assays

Substances

  • Adjuvants, Immunologic
  • Cancer Vaccines
  • Lipids
  • Lipopeptides
  • Pam(3)CSK(4) peptide
  • RNA, Messenger
  • Ovalbumin